Post Reply
3961-3980 of 10899
From the price level, good news has been priced in!junction ( Date: 13-May-2010 16:44) Posted:
Results out only on 26 May. Now charging. Must be very good results or some takeover story. Anyone got news? |
|
BIG is the most "LP" counter.
Clinical Results GREAT!!!
How will investors view the stock now?
BIG exceeded concensus numbers and had great clinical success. Trials proved stent better than JNJ & Boston Scientific established stents.
So Boss , how Clinical Results good or not?
topdog22 ( Date: 25-May-2010 22:59) Posted:
Nobori Clinical Results Presented 5/25
15
Conclusions
1. NOBORI 1 Clinical Trial met its primary endpoint in both phases
showing non-inferiority of Nobori verus Taxus Express and
Taxus Liberté with respect to in-stent late loss
2. Most angiographic and IVUS parameters (diameter stenosis instent,
mean plaque area and volume and volume obstraction)
significantly favoured Nobori stent
3. Angiographic restenosis rate was significantly lower in Nobori vs
Taxus (0.4% vs 4.6%; p<0.01)
4. Clinical efficacy and safety of Nobori stent up to 2 years is
reflected by:
a. Absence of clinically driven TLR
b. Low TVF Rate
c. No stent thrombosis up to 2 years FU (with 25 % of DAP @ 2y.) |
|
Nobori Clinical Results Presented 5/25
15
Conclusions
1. NOBORI 1 Clinical Trial met its primary endpoint in both phases
showing non-inferiority of Nobori verus Taxus Express and
Taxus Liberté with respect to in-stent late loss
2. Most angiographic and IVUS parameters (diameter stenosis instent,
mean plaque area and volume and volume obstraction)
significantly favoured Nobori stent
3. Angiographic restenosis rate was significantly lower in Nobori vs
Taxus (0.4% vs 4.6%; p<0.01)
4. Clinical efficacy and safety of Nobori stent up to 2 years is
reflected by:
a. Absence of clinically driven TLR
b. Low TVF Rate
c. No stent thrombosis up to 2 years FU (with 25 % of DAP @ 2y.)
Biosensors Launches BioMatrix Flex™ Drug-Eluting Stent Singapore 24 May 2010 – Biosensors International Group, Ltd (“Biosensors” or the “Company”, Bloomberg : BIG SP) today announced the launch of its BioMatrix Flex™ drug-eluting stent system in major European markets and selected regions in the Middle East, Africa and Asia. An extension of the company’s BioMatrix™ drug-eluting stent system, the BioMatrix Flex™ stent has received CE Mark approval for a comprehensive range of indications, including STEMI (ST Elevated Myocardial Infarction), Acute Coronary Syndromes and Diabetes Mellitus. The BioMatrix Flex™ stent incorporates a new stent platform which combines a curved strut connector with the established Quadrature Link™ design of the existing platform. The unique combination of a Biosensors-developed abluminal biodegradable polymer and proprietary limus drug, Biolimus A9™ (BA9™), pioneered with the BioMatrix™ stent, remains unchanged. The BioMatrix Flex™ stent has also removed the need for a primer coating to adhere the polymer and drug to the stent, with a Biosensors’ proprietary process now applying the polymer and drug directly onto the stent struts. “Since launching BioMatrix in 2008, Biosensors has helped physicians around the world offer improved treatment options to patients suffering from complex cardiovascular disease,” said Jeffrey B. Jump, Managing Director of Biosensors Europe. “With BioMatrix Flex, we are continuing our commitment to develop innovative medical products that help improve patients’ lives.” The BioMatrix Flex™ stent has been studied extensively in both pre-clinical and clinical settings, including the groundbreaking 1,707-patient LEADERS study, the results of which were published in The Lancet in October 2008. In that trial, the first head-to-head randomized trial between two drug-eluting stent systems in a ‘real world, all comers’ population using a clinical primary endpoint, the BioMatrix Flex™ stent demonstrated equivalent safety and efficacy to the Cypher® Select™ stent, based on ninemonth clinical and angiographic follow-up data. In the two-year LEADERS results, presented at the Transcatheter Cardiovascular Therapeutics conference (TCT) in September 2009, the BioMatrix Flex™ stent continued to demonstrate equivalent safety and efficacy as compared to the Cypher® Select™ stent, with an increasing trend towards a long-term safety benefit in favor of the BioMatrix Flex™ stent. Further significant new data from LEADERS is to be presented at EuroPCR, as part of the Hot Line 1 Late Breaking Registries and Trial Update session on 25 May.
Things look promising for this one, though...
I guess it "show time" for BIG. Will they give us a "really BIG show"?
Based on all that has transpired, I believe (as previously stated) that there will be an earnings surprise to the upside causing the target price to be revalued to more than $1.25. That the Terumo trial results will be excellent proving the BIG stent to be a clinical outcome leader. That the trading range of BIG will finally return to $1.00+ based on a growing "business as usual".
If BIG has additional insight into how it WILL enhance shareholder value, either through the:
1) spin-off of its JWMS JV, by Floating that JV in HongKong or Shanghai and the distribution of those shares to current BIG shareholders, worth .50+ per BIG share
2) an M&A for BIG, worth $1.10++ per BIG Share
3) BIG lisiting on Hong Kong or Shang Hai or U.S. worth $1.10+++
BIG shares could once again recapture the momentum they had in the Spring of 2006.
Only another few days for the BIG unveiling.
Are they at the
Shanghai Expo?...
Biosensors progam at the EuroPcr meeting in Paris from 25th May.
Visit us at our booths...
F28+F30+F31
This year, Biosensors is pleased to welcome you to one of its three exihibition booths.
Come and discover our new
Abluminal Biodebgradable Polymer DES – BioMatrix FlexTM
join our contest or have a rest in our lounge!
Late Breaking Trial
“Biolimus Eluting-Stent Reduces Mortality in Patients with High SYNTAX Scores in the All-Comers LEADERS trial”
Tuesday 25th May, 2010 – 13:30- 14:55 – Main Arena
J. Wykrzykowska
Attend our Symposium
New Insights into the LEADERS Trial
"Long Term Benefits of Biodegradable Polymer DES in Complex Patient Population"
Wednesday 26th May, 2010 - 12:00-13:30 - Room Bagatelle (Level 4)
Chairperson: P.W.Serruys
Co-Chairperson: B. Meier
For Info.
Lai ya! ... 
Is true la!!!!!Get ready to Chiong !!!!!!!!!!!!!!!!!!!!!!!!!!!
susan66 ( Date: 18-May-2010 23:11) Posted:
I think so too, it's just a matter of time. After the surge last Thursday from 0.77 to 0.825, it has been preparing for the next one. These few days very stable when market sentiment poor but managed to support >0.80. So can get ready liao!  |
|
I think so too, it's just a matter of time. After the surge last Thursday from 0.77 to 0.825, it has been preparing for the next one. These few days very stable when market sentiment poor but managed to support >0.80. So can get ready liao!
lai ya.!...
BIG!!!!!!!!!!!!!!!!!Lai Loh!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
| 15:01:01 |
0.825 |
40,000 |
Buy Up |
| 14:59:27 |
0.825 |
15,000 |
Buy Up |
| 14:59:24 |
0.825 |
50,000 |
Buy Up |
| 14:59:21 |
0.825 |
24,000 |
Buy Up |
| 14:59:18 |
0.825 |
20,000 |
Buy Up |
| 14:59:17 |
0.825 |
50,000 |
Buy Up |
| 14:59:17 |
0.825 |
80,000 |
Buy Up |
| 14:59:16 |
0.825 |
120,000 |
Buy Up |
| 14:59:13 |
0.825 |
200,000 |
Buy Up |
| 14:58:40 |
0.825 |
30,000 |
Buy Up |
| 14:58:12 |
0.825 |
20,000 |
Buy Up |
| 14:57:46 |
0.820 |
1,147,000 |
Buy |
XiaoMaGe888 ( Date: 13-May-2010 16:13) Posted:
BIG!!!!!!!!!!!Lai liao!!!!!!!!!!!!!!!!!!!!!!!! |
|
As long as profit is okay to me! Ha. ha.. ha...
AK_Francis ( Date: 13-May-2010 16:27) Posted:
| Ha ha, can't blame Greece's issue, then had buang all my holding. Otherwise, few K more for Heineken liao. |
|
In Terumo's audio conference on 12th May 2010, they mentioned that sales in Europe, Asia have increase for their interventional cardiology section, which includes Nobori DES, their own cathethar, etc.
They specifically mentioned that Nobori has increased sales, which contribute to the results. - No mention of quantum of increase, and whether it is a Q-on-Q increase or Yr-on-YR increase.
Are we also able to extrapolate that Biosensors' own bio-matrix sales have also increased ? (Any body got any ideas ?)
For info. Not a call to buy/sell.
Probably. one of the reasons, why Biosensors started to move yesterday, was because Shandong Weigao announced their results, and Its 50 % owned JW Medical System (JWMS for short) make a profit of 34,915 million RMB.
THis is approximately equivalent to US$4.8m to US$5 m. (Depending on the FX rate used)
If you compare with last qtr, Biosensors announced that their 50 % of JWMS profit was US$5.732 m of which US$2.6 m was a govt grant.
IF THERE IS NO GOVT grant for this current Qtr, then JWMS is contributing actual earnings of US$4.8 m to US$5.00 m.
If Terumo's licensing contribution remains constant at US$2.5 m, then Biosensors will have earned approx US$7.3 m to US$7.5m, just from external sources for the current Qtr.
Also, their 9-mths earnings todate is approx US$22.9 m, implying that they would have already earned approx US$30m for the whole year, without considering their own sales.
THis US$30m is closer to Nomura's projection of US$33m, rather than Credit Suisse projection of US$24.9 m.
Above is my own estimates. For info - Not a call to buy/sell.
